Director Diagnostic Marketing (Solid Tumor)

NanoString® Technologies, Inc.
Job Location
Seattle, WA 98109
Competitive Comp

Benefits include but are not limited to: Medical, Dental, Vision, Stock Options, ESPP, Matching 401K, transportation assistance, wellness reimbursement, PTO, and more...

Job Description

Job Summary:

The Director Diagnostic Marketing will be responsible for establishing brand strategy for our solid tumor assays and implementing operational plans which ensures the continued growth of the Company's breast cancer diagnostic product the Prosigna Breast Cancer Assay.  She/he will have P&L responsibility and is expected to maximize available resources to ensure growth for the company's diagnostic products. The successful candidate will report to, and will oversee all aspects of diagnostic brand plan development in complex and competitive markets.

The Director Diagnostic Marketing will establish a clear vision for the solid tumor brands and will establishing clear objectives which will form the foundation of field sales plans.  The successful candidate will also guide the development of external product champions and serve as a hands-on leader who drives cross-functional collaboration, by creating innovative programs which ensure the growth of the solid tumor diagnostic products in a new, decentralized market opportunity. 

Responsibilities and scope includes:

  • Lead the development and execution of strategic marketing and life-cycle plans including developing long range forecast, commercial budget and tactical brand plans
  • Proven ability to conceptualize and articulate a clear vision for the brand that engages all functional areas and stakeholders
  • Develop customer/patient centric innovative programs which compliment field promotional efforts
  • Cultivate strong customer relationships and lead KOL management
  • Define and lead critical market research initiatives which uncover market opportunities and challenges
  • Partner with sales, medical affairs, global marketing, market access, legal, and regulatory to ensure aligned objectives and implementation of brand strategies
  • Proven team player with ability to frequently and successfully collaborate cross-functionally
  • Excellent written/verbal communication at all times. Experienced in delivering complex messages to various internal and external customers with a track record of effective and influential presentations.


  • 8-10 years related industry experience with 4 + years of clinical marketing experience
  • At least 2-4 years of Hematology/Oncology experience is required, breast cancer experience is preferred
  • Proven history of marketing leadership , creativity, and strategic capabilities, across multidisciplinary teams
  • In depth knowledge of payers, patient access, physician networks, Federal & pathways companies
  • Significant experience managing high complexity projects, creatively overcoming marketing challenges and effectively prioritizing

*National and International travel is required

How to Apply
About Our Organization

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications.

NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer.

Organizations performing cancer research, biomarker validation and screening, and next-generation sequencing validation are rapidly adopting the nCounter® Analysis System. By providing simple, multiplexed digital profiling of single molecules, the NanoString platform represents a natural, digital downstream companion to next-generation sequencing and enables researchers to embark on studies that were previously inconceivable.

Leading researchers and institutions are finding that NanoString's nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues.

In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company's goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics.

At Nature, Johns Hopkins' Gundula Bosch describes her graduate program that aims to get doctoral students thinking about the big picture.

Patricia Fara writes about childcare funding, and women in science and science history at NPR.

National Institute of Environmental Health Sciences researchers have visualized the career paths of former postdocs.

A new survey from the Pew Research Center finds that half of women working in STEM have experienced gender discrimination at work.